Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab pretreatment in diabetic vitrectomy
NCT00656435Phase 3Completed
- Sponsor
- National Taiwan University Hospital
- Start
- Dec 2006
- Primary completion
- Aug 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label trial of bevacizumab in proliferative diabetic retinopathy (PDR), sponsored by National Taiwan University Hospital. Primary endpoints: Severity of intraoperative bleeding and Vitreous clear-up time at 6 months. Started Dec 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT00656435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00656435.